ICON Partners with Korea National Enterprise for Clinical Trials
ICON plc
, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and
Korea National Enterprise for Clinical Trials
(KoNECT) today announced they have signed a partnership agreement that aims to advance the clinical trials industry in South Korea.
Through the agreement, ICON and KoNECT will collaborate on a series of educational events for local and multinational pharmaceutical companies, investigators and industry officials. The programmes aim to further enhance the already high standards of clinical research in South Korea and will kick off with an oncology trials seminar in Seoul on October 26th.
“South Korea has become a key country for clinical development and ICON has had a well-established presence there since 2005,” commented Wei Ming Goh, ICON’s Vice President, Asia-Pacific. “Our agreement with KoNECT supports our mutual interest in developing and growing the clinical research industry in South Korea and demonstrates our on-going commitment to the Asia Pacific region.”
KoNECT President, Professor Sang-Goo Shin, added, “We are delighted to collaborate with a leading clinical research organisation such as ICON that has a wealth of expertise in both local and global clinical development programmes. Together we can develop high quality clinical research professionals and a clinical trials infrastructure that can support the increased demand from local and global pharma companies.”
ICON is one of the leading CROs in Asia-Pacific, employing over 1,400 staff in the region from locations in 13 countries. Learn more about ICON’s capabilities in Asia-Pacific at
http://www.iconplc.com/emerging-markets/
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
